A flurry of recent studies has implicated KIF18A as a tractable therapeutic vulnerability specifically in cancers with aneuploidy, CIN, weakened APC/C activity, and SAC persistence [142,143,144,145,146]. The gene discussed is KIF18A; the disease is cancer.